koe 172°
Section 3 - 510(k) Summary JAN 3 1 2007
Re: 061720
This 510(k) summary of safety and effectiveness for the Cosmelight Intense Pulsed Light
system by Penntack Enterprises Inc. is submitted in accordance with the requirements of
the Safe Medical Devise Act (SMDA) of 1990 and follows the office of Devise Evaluation
(ODE) guidance concerning the organization and content of a 510(k) summary
Applicant : Penntack Enterprises Inc. _ __
Address : 3321 NW 79 ST. Miami, FL 33147
305-835-0411
“Common Name’ Ine uGTigt Sue
Common Name : Intense Pulsed Light System
Classification Name} Laser surgical instrument for use in general and plastic and
dermatology.
21 CFR 878.4810
Product Code: GEX
Panel: 79
Legally-marketed | The Cosmelight is substantially equivalent to the following currently
Predicate Devices: | marketed devices:
Lumenis Inc IPL Quantum, K020839
Palomar Inc. EsteLux, K020453
McCue Ple. McCue Energist ULTRA, K040659
DDD A/S, Ellipse PL, K060516
System Description:| The Cosmelight Intense Pulsed Light System is comprised of the |
following main components:
¢ Acontrol console unit. |
e A control and color display panel.
¢ Two removable handpieces with an integrated trigger switch
and a Cooling System (a cooling device integrated into the
handpieces. Quick Cool Handle ( QCH )
e Power supply.
Indicated Use : The Cosmelight Intense Pulsed Light System (and its accessories)
| are indicated for use in surgical, aesthetic and cosmetic
| | applications (requiring photothermolysis, photocoagulation and
| | dermatology) in the treatment of acne, various benign pigmented |
lesions and hair removal as follow: |
| 1. Intense Pulse Light Energy Wavelengths from 400 - 950 nm |
are indicated for the treatment of acne.
2. Intense Pulse Light Energy Wavelengths from 560 - 120 Onm |
Lo are indicated for the treatment of benign pigmented (epidermal
1

0617 7°
and coetaneous) lesions including warts, scars and striae. For the |
treatment of benign (cutaneous) vascular lesions including port
wine stains, hemangiomas, facial, truncal and leg telangiectasias,
rosacea, melasma, angiomas and spider angiormas, poikiloderma
of civatte, leg veins, facial veins and venous malformations.
3. Intense Pulse Light Energy Wavelengths from 700 - 1200 nm
| are indicated for the treatment of unwanted hair (i.e., hair
' removal).
| 4. Quick Cool Handle (QCH )
The Quick Cool Handle is indicated for use in cooling the |
epidermis at the treatment Site prior to, during and after
light or laser treatment in general surgery, plastic surgery
And dermatology to :
e Reduce pain associated with light or laser treatments
(via partial anesthesia from Cooling). |
e Minimize thermal injury, including thermal necrosis, to
non target skin and skin Structures during light or laser
treatments, thus reducing the possibilities of scabbing,
scarring, hypo and / or hyper pigmentation.
e Allows the use of higher light or iaser fluences for light
or laser treatments (such as for hair removal and the treatm
of vascular or pigmented lesions.
Performance Data : | The differences in specifications of the Cosmelight system and the
Predicate devices do not result in different performance or raise |
_ ___| new questions of safety and efficacy. |
Conclusion : Based on the foregoing, the Cosmelight system is substantially
Equivalent to the legally-marketed predicate devices mentioned
iabove.
2

= J DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
om Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Penntack Enterprises, Inc.
% Mr. Paul Pena
Director
3321 NW 79" Street
Miami, Florida 33147
JAN 3 9 2007

Re: K061720

Trade/Device Name: Cosmelight

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in

dermatology

Regulatory Class: Class II

Product Code: GEX

Dated: November 24, 2006

Received: November 28, 2006
Dear Mr. Pena:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class I] (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean.
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Mr. Paul Pena
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115 Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. /

Sincerely pourg,

!
{4 ¢

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health
Enclosure

| a
!
| |
! Indications for Use :
f s1000 Number (if known): K061720. |
4 |
: Device Name: Cosmelight |
f dications for Use: |
[The Cosmelight Intense Pulsed Light System (and its accessories) are indicated for use |
‘i surgical, aesthetic and cosmetic applications (requiring photothermolysis,
i photocoagulation and dermatology) in the treatment of acne, various benign pigmented |
| Testons and hair removal as follow:
1. Intense Pulse Light Energy Wavelengths from 400 - 950 nm are indicated for the
i treatment of: inflammatory acne.
i 2. Intense Pulse Light Energy Wavelengths from 560 - 1200 nm are indicated for the
i: Wreatment of: benign pigmented (epidermal and coetaneous) lesions including warts, |
| iscars and striae. For the treatment of benign (cutaneous) vascular lesions including |
‘port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea,
|: bnelasma, angiomas and spider anglormas, poikiloderma of ctvatte, leg veins, facial :
i: jvelns and venous malformations. |
: 3. Intense Pulse Light Energy Wavelengths from 700 - 1200 nm are indicated for the
i sreatment of: unwanted hair (Le., hair removal). |
nd ;
: Prescription Use X OR Over-The-Counter Use |
| (Part 21 CFR 801 Subpart D ) (21CFR 807 Subpart C) |
7 :
ivf 1
|
; \ PLEASE DO NOT WRITE BELOW THIS LINE — CONTINUE ON ANOTHER PAGE
4 |
! ! a i
: (Divisior. sign-G)
d Division of General, Restorative. | |
: and Neurological Devices
i lke? |
7 510(k) Number... S-.. .- |
|
1 |

